CHICAGO — Treatment with a thrombin-suppressing direct oral anticoagulant (DOAC) probably didn't stem the progression of heart failure (HF) in the COMMANDER HF trial, but it could well have cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback